Novel investigations on the protective role of the FVIII/VWF complex in inhibitor development-Reference-Cited by-同舟云学术

Novel investigations on the protective role of the FVIII/VWF complex in inhibitor development

Published:2014-06-26 Issue: Volume:20 Page:2-16
ISSN:1351-8216
Container-title:Haemophilia
language:en
Short-container-title:Haemophilia

Author:

Mannucci P. M.¹,Shi Q.²,Bonanad S.³,Klamroth R.⁴

Affiliation:

1. Scientific Direction; IRCCS Ca’ Granda Foundation Maggiore Hospital; Milan Italy

2. Medical College of Wisconsin; Blood Research Institute; Milwaukee WI USA

3. Hospital Universitari i Politècnic La Fe; Valencia Spain

4. Klinik für Innere Medizin-Angiologie; Hämostaseologie und Pneumologie/Hämophiliezentrum und Gerinnungssprechstunde; Vivantes-Klinikum im Friedrichshain; Berlin Germany

Publisher

Wiley

Subject

Genetics(clinical),Hematology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/hae.12465/fullpdf

Reference48 articles.

1. French previously untreated patients with severe hemophilia A after exposure to recombinant factor VIII: incidence of inhibitor and evaluation of immune tolerance;Rothschild;Thromb Haemost,1998

2. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group;Lusher;N Engl J Med,1993

3. Incidence of factor VIII inhibitor development in hemophilia A patients treated with less pure plasma derived concentrates;Biasi;Thromb Haemost,1994

4. Incidence of factor VIII inhibitor development in severe hemophilia A patients treated only with one brand of highly purified plasma-derived concentrate;Guérois;Thromb Haemost,1995

5. A multicenter study of recombinant factor VIII (Recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A;Bray;The Recombinate Study Group. Blood,1994

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Emicizumab and unmet needs of patients with hemophilia a who are managed with replacement therapies;Expert Review of Hematology;2024-09-12

2. Immunogenicity of Therapeutic Biological Modalities - Lessons from Hemophilia A Therapies;Journal of Pharmaceutical Sciences;2023-09

3. Association between interleukin-2 (rs2069762) gene polymorphism and FVIII inhibitor development in Indonesian patients with severe hemophilia A;Medical Journal of Indonesia;2023-03-08

4. Plasma‐derived FVIII/VWF complex shows higher protection against inhibitors than isolated FVIII after infusion in haemophilic patients: A translational study;Haemophilia;2022-06-02

5. An update on the ‘danger theory’ in inhibitor development in hemophilia A;Expert Review of Hematology;2019-04-25